GlobeNewswire: Verona Pharma plc Contains the last 10 of 230 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:25:44ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/04/2839234/0/en/Andrew-Fisher-Joins-Verona-Pharma-as-General-Counsel.html?f=22&fvtc=4&fvtv=33118Andrew Fisher Joins Verona Pharma as General Counsel2024-03-04T07:00:00Z<![CDATA[LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.]]>https://www.globenewswire.com/news-release/2024/02/29/2837626/0/en/Verona-Pharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=33118Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update2024-02-29T07:00:00Z<![CDATA[PDUFA Target Action Date for ensifentrine of June 26, 2024]]>https://www.globenewswire.com/news-release/2024/02/15/2829622/0/en/Verona-Pharma-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=33118Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update2024-02-15T07:00:00Z<![CDATA[LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2024/02/01/2821679/0/en/Michael-Austwick-Joins-Verona-Pharma-as-Non-Executive-Director.html?f=22&fvtc=4&fvtv=33118Michael Austwick Joins Verona Pharma as Non-Executive Director2024-02-01T07:00:00Z<![CDATA[LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director.]]>https://www.globenewswire.com/news-release/2024/01/03/2803027/0/en/Verona-Pharma-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=33118Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T07:00:00Z<![CDATA[LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.]]>https://www.globenewswire.com/news-release/2024/01/02/2802416/0/en/Verona-Pharma-enters-into-Debt-Facility-of-up-to-400-Million-with-Oxford-Finance-and-Hercules-Capital.html?f=22&fvtc=4&fvtv=33118Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital2024-01-02T07:00:00Z<![CDATA[Strengthens financial flexibility to support the Company’s continued growth Strengthens financial flexibility to support the Company’s continued growth]]>https://www.globenewswire.com/news-release/2023/11/17/2782369/0/en/Verona-Pharma-s-President-and-CEO-David-Zaccardelli-Wins-Executive-of-the-Year-SCRIP-Award.html?f=22&fvtc=4&fvtv=33118Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award2023-11-17T07:00:00Z<![CDATA[LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership.]]>https://www.globenewswire.com/news-release/2023/11/08/2775821/0/en/Verona-Pharma-Announces-November-2023-Investor-Conference-Participation.html?f=22&fvtc=4&fvtv=33118Verona Pharma Announces November 2023 Investor Conference Participation2023-11-08T07:00:00Z<![CDATA[LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023:]]>https://www.globenewswire.com/news-release/2023/11/02/2771927/0/en/Verona-Pharma-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=33118Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update2023-11-02T07:04:00Z<![CDATA[US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD]]>https://www.globenewswire.com/news-release/2023/10/19/2762877/0/en/Verona-Pharma-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html?f=22&fvtc=4&fvtv=33118Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update2023-10-19T06:00:00Z<![CDATA[LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2023 on Thursday, November 2, 2023 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.]]>